​​Heavy Ion Therapy for Pancreatic Cancer Now Covered with No Out-of-pocket Costs; Full-Scale Clinical Research Treatment Underway​

As China's first hospital utilizing domestically-developed heavy ion therapy system and the only facility worldwide operating two such systems, Gansu Wuwei Cancer Hospital has treated over 2,000 patients across 50+ conditions—including lung, pancreatic, and liver cancers—through five years of clinical practice. Its clinical efficacy and patient survival rates have reached internationally advanced levels. The hospital has achieved ​​eight world-first breakthroughs​​:Globally the only institution operating dual heavy ion therapy systems; Performed the largest number of single-fraction treatments completed within one day worldwide; Pioneered precision heavy ion therapy under respiratory-gating technology; First globally to treat bladder cancer with real-time bladder volume monitoring; Innovated single-session heavy ion therapy using surgical spacer placement between organs and tumors; China’s first developer of 360° rotatable ion therapy chairs; World’s first to successfully treat multiple cardiac tumor cases with heavy ions; Globally the first to implement holistic lifetime health management alongside heavy ion therapy.

To advance China’s heavy ion therapy capabilities, the hospital is deepening clinical research and accelerating technological upgrades. It now launches the ​​Phase II Clinical Study: Carbon Ion Radiotherapy Concurrent with Gemcitabine Chemotherapy for Locally Advanced Pancreatic Cancer​​. This initiative aligns with international standards to establish China-specific clinical protocols for pancreatic cancer treatment via heavy ion systems, ultimately pursuing superior patient outcomes.

​​Phase II Clinical Study: Carbon Ion Radiotherapy Concurrent with Gemcitabine Chemotherapy for Locally Advanced Pancreatic Cancer​​

Our hospital is conducting a clinical trial combining ​​carbon ion radiotherapy​​ with ​​concurrent gemcitabine chemotherapy​​ for locally advanced pancreatic cancer. As an internationally advanced precision radiotherapy technology, carbon ion therapy serves as a ​​localized tumor control​​ method. This study aims to evaluate the ​​safety and efficacy​​ of this approach, exploring optimal treatment strategies for pancreatic cancer patients.

Eligibility Criteria

​​1. Aged 18–70 years​​ with ​​histopathologically confirmed pancreatic cancer​​;

2. Meets criteria for ​​locally advanced pancreatic cancer​​（no distant metastasis, tumor diameter ≤6 cm）;

3. No prior ​​surgery​​, ​​radioactive seed implantation​​, or other local interventions;

​​4. Medically fit​​ for treatment（no organ dysfunction）;

​​5. Voluntary participation​​ with commitment to complete therapy and follow-ups.

Final eligibility determined by investigators per study protocol.

Patient Benefits

1.​​ Heavy ion therapy costs fully covered​​ by hospital research grants;

​​2. Personalized treatment plans​​ developed by a ​​multidisciplinary team (MDT)​​ specialized in pancreatic cancer;

​​3. Close post-treatment monitoring​​ with tailored follow-up care.

Contact

联系人：

Wuwei Heavy Ion Center​​ Gansu Wuwei Cancer Hospital

   Dr. Chen Weizuo: +86 135 1935 1968

​​Lanzhou Heavy Ion Center​​ Gansu Wuwei Cancer Hospital

   Dr. Li Xiaojun: +86 131 5016 0200